Tikomed: TikoMed's ILB mobilizes and modulates key growth fa

Tikomed: TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all neuroinflammation-driven diseases including ALS

VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced

Related Keywords

Sweden , Anders Kristensson , Kostenloser Wertpapierhandel , Ann Logan , Prnewswire Tikomed , University Of Warwick , Scientific Director , Axolotl Consulting , Regenerative Medicine , Amyotrophic Lateral Sclerosis , Traumatic Brain Injury , Tikomed , Emobilizes , Modulates , Growth , Actors , Trigger , Cascade , Neuroprotective , Mechanisms , Bible , Target , Neuroinflammation , Riven , Diseases , Ncluding ,